AT496635T
Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
Abstract
Diagnostic to lump force and assay using for anti-vibration anti-estrin processing method and kit of the box pharmacological moving. PCDGF (GP88) growth factor layer for improving instruction to send the lump force and a estrin processing the resistance of pharmacological moving. Method and reagent box of the invention is used for appraise the new biologic a user to the force lump and method for determining wherein the patient for is a anti-estrogen (comprising a detecting Moxifen) is therapy object.
Term
Term ended
Expired 14 June 2022, 4.3 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
100 members in 15 offices
Priority claims2
| Document | Office | Kind | Date |
|---|---|---|---|
| 88084201 | United States of America | A | |
| 0218550 | United States of America | W |
Members100
| Document | Office | Kind | |
|---|---|---|---|
| CA2290602A1 | Canada | A1 | |
| WO9852607A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU7797898A | Australia | A | |
| EP1011723A1 | European Patent Office (EPO) | A1 | |
| US6309826B1 | United States of America | B1 | |
| EP1011723A4 | European Patent Office (EPO) | A4 | |
| US2002025543A1 | United States of America | A1 | |
| US2002061859A1 | United States of America | A1 | |
| US2002094966A1 | United States of America | A1 | |
| US2002183270A1 | United States of America | A1 | |
| CA2450590A1 | Canada | A1 | |
| CA2450666A1 | Canada | A1 | |
| WO02102229A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO02102306A2 | World Intellectual Property Organization (WIPO) | A2 | |
| US2003092661A1 | United States of America | A1 | |
| WO02102306A3 | World Intellectual Property Organization (WIPO) | A3 | |
| US2003108950A1 | United States of America | A1 | |
| EP1356824A2 | European Patent Office (EPO) | A2 | |
| WO02102229A3 | World Intellectual Property Organization (WIPO) | A3 | |
| EP1011723B1 | European Patent Office (EPO) | B1 | |
| US2003215445A1 | United States of America | A1 | |
| AT254476T | Austria | T | |
| ATE254476T1 | Austria | T1 | |
| DE69819911D1 | Germany | D1 | |
| US6670183B2 | United States of America | B2 | |
| EP1356824A3 | European Patent Office (EPO) | A3 | |
| DK1011723T3 | Denmark | T3 | |
| EP1399739A2 | European Patent Office (EPO) | A2 | |
| EP1404365A2 | European Patent Office (EPO) | A2 | |
| US6720159B1 | United States of America | B1 | |
| PT1011723E | Portugal | E | |
| SI1011723T1 | Slovenia | T1 | |
| CA2504178A1 | Canada | A1 | |
| WO2004039244A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO02102306A8 | World Intellectual Property Organization (WIPO) | A8 | |
| KR20040043128A | Republic of Korea | A | |
| AU2003284190A1 | Australia | A1 | |
| US2004131618A1 | United States of America | A1 | |
| WO2004060280A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU2003296432A1 | Australia | A1 | |
| AU2003296432A8 | Australia | A8 | |
| ES2213906T3 | Spain | T3 | |
| DE69819911T2 | Germany | T2 | |
| US6824775B2 | United States of America | B2 | |
| US6881548B2 | United States of America | B2 | |
| WO2004039244A3 | World Intellectual Property Organization (WIPO) | A3 | |
| JP2005514907A | Japan | A | |
| WO2004060280A3 | World Intellectual Property Organization (WIPO) | A3 | |
| EP1563308A2 | European Patent Office (EPO) | A2 | |
| JP2005524602A | Japan | A | |
| CN1682111A | China | A | |
| JP2006504104A | Japan | A | |
| EP1404365A4 | European Patent Office (EPO) | A4 | |
| HK1083366A1 | Hong Kong, China | A1 | |
| EP1399739A4 | European Patent Office (EPO) | A4 | |
| US7091047B2 | United States of America | B2 | |
| EP1563308A4 | European Patent Office (EPO) | A4 | |
| AU2002315060B2 | Australia | B2 | |
| AU2002312462B2 | Australia | B2 | |
| CN100397081C | China | C | |
| WO02102229A9 | World Intellectual Property Organization (WIPO) | A9 | |
| JP4242836B2 | Japan | B2 | |
| KR20090045423A | Republic of Korea | A | |
| JP2009109489A | Japan | A | |
| US2009203047A1 | United States of America | A1 | |
| US7592318B2 | United States of America | B2 | |
| JP2009215302A | Japan | A | |
| JP4348178B2 | Japan | B2 | |
| CN101584862A | China | A | |
| JP4392238B2 | Japan | B2 | |
| US2010021475A1 | United States of America | A1 | |
| US2010111928A1 | United States of America | A1 | |
| KR20100050580A | Republic of Korea | A | |
| KR100972053B1 | Republic of Korea | B1 | |
| AU2003284190B2 | Australia | B2 | |
| KR100980105B1 | Republic of Korea | B1 | |
| AU2010246504A1 | Australia | A1 | |
| EP1404365B1 | European Patent Office (EPO) | B1 | |
| AT496635TThis record | Austria | T | |
| ATE496635T1 | Austria | T1 | |
| DE60239059D1 | Germany | D1 | |
| ES2359494T3 | Spain | T3 | |
| US8007997B2 | United States of America | B2 | |
| JP4763032B2 | Japan | B2 | |
| AU2010246504B2 | Australia | B2 | |
| EP1563308B1 | European Patent Office (EPO) | B1 | |
| AT529743T | Austria | T | |
| ATE529743T1 | Austria | T1 | |
| US2012087918A1 | United States of America | A1 | |
| ES2395125T3 | Spain | T3 | |
| KR101258254B1 | Republic of Korea | B1 | |
| JP2013139473A | Japan | A | |
| US8512960B2 | United States of America | B2 | |
| EP1399739B1 | European Patent Office (EPO) | B1 | |
| US8911950B2 | United States of America | B2 | |
| ES2531368T3 | Spain | T3 | |
| CA2290602C | Canada | C | |
| JP2015227369A | Japan | A | |
| CN101584862B | China | B | |
| CA2504178C | Canada | C |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Ceased as to paragraph 5 lit. 3 law introducing patent treatiesCeasedRER | RER |
Numbers
- Application
- 2739838
Titles2
- German
- VERFAHREN UND ZUSAMMENSETZUNGEN ZUR HEMMUNG, PRÄVENTION ODER VERRINGERUNG DES TUMORZELLWACHSTUMS BEI PATIENTEN, DIE GEGEN DIE ANTINEOPLASTISCHEN WIRKUNGEN EINER ANTIÖSTROGEN- THERAPIE RESISTENT SIND
- English
- METHOD AND COMPOSITIONS FOR INHIBITING, PREVENTING OR REDUCING TUMOR CELL GROWTH IN PATIENTS RESISTANT TO THE ANTINEOPLASTIC EFFECTS OF ANTI-OROGEN THERAPY
Classification
- CPC, 11
- C07K16/22
- A61K38/00
- A61K2039/505
- A61P15/00
- C07K14/475
- A61P35/00
- C07K2317/73
- A61P43/00
- C07K2317/76
- C12N2799/026
- G01N2333/475
- IPC, 17
- A61K31 138
- A61K38 00
- A61K39 00
- A61K39 38
- A61K39 395
- A61K45 00
- A61K48 00
- A61P35 00
- A61P43 00
- C07K14 475
- C07K16 22
- C07K16 30
- C12N15 09
- C12Q1 02
- C12Q1 68
- G01N33 574
- G01N37 00